XLO FY 2023 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$28M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$79M

Net Income

-$76M

EPS (Diluted)

$-2.78

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$69M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$61M

Total Liabilities

$24M

Stockholders' Equity

$37M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$79M	-$89M	+11.2%
Net Income	-$76M	-$88M	+13.4%